Small platform supporting state-of-the-art technology for fast PCR protocols introduced at American Society of Human Genetics meeting in Montreal The new LightCycler Nano instrument shares the ...
PENZBERG, Germany--(BUSINESS WIRE)-- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Exiqon (NASDAQ OMX: EXQ) join marketing forces for Roche Applied Science´s RealTime ready assays and Exiqon`s miRCURY LNA™ ...
Roche has an ongoing program to develop a real-time PCR assay that detects mutations in the PI3K oncogene. The assay will run on Roche's cobas ® 4800 System. Roche intends to make the PI3K PCR assay ...
PENZBERG, Germany--(BUSINESS WIRE)-- Roche (SIX:RO)(SIX:ROG)(OTCQX:RHHBY) and Ghent University (Belgium) have signed an agreement for the use of Roche's LightCycler® 1536 Instrument in various cancer ...
Large-scale, PCR-based gene analysis can only be performed if signals are generated, captured and analyzed in a highly reproducible manner. More precisely, thermal control, optical readout and the ...
Technology to be used in Roche’s new line of RealTime ready qPCR assays. Roche Diagnostics and Exiqon amended a 2005 license and distribution agreement for the Universal ProbeLibrary (UPL), which is ...
The new LightCycler Nano instrument shares the state-of-the-art technology of the LightCycler portfolio, producing high quality data in qPCR, genotyping, and high resolution melting on a small ...
Roche announced that the company has obtained a worldwide co-exclusive license for the biomarker PI3K (phosphoinositide 3-kinase) from QIAGEN to develop real-time and endpoint PCR diagnostic assays.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results